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Members of the vasodilator-stimulated phosphopro-
tein (VASP) family are important regulators of actin
cytoskeletal dynamics whose functions and protein-pro-
tein interactions are regulated by phosphorylation by
the cAMP-dependent protein kinase (PKA). Herein, we
show that phosphorylation of VASP is dynamically reg-
ulated by cellular adhesion to extracellular matrix. De-
tachment of cells stimulated PKA activity and induced
PKA-dependent phosphorylation of VASP and the re-
lated murine-Enabled (Mena) protein. VASP and Mena
were rapidly dephosphorylated immediately following
reattachment but showed an intermediate level of phos-
phorylation during active cell spreading. This pattern
correlated closely with adhesion-dependent changes in
PKA activity. The in vivo interaction of VASP with the
Abl tyrosine kinase, shown here for the first time, was
readily apparent in adherent cells, lost following cellu-
lar detachment, and induced upon reattachment to ma-
trix. Importantly, inhibition of PKA activity prevented
phosphorylation of VASP and dissociation of VASP-Abl
complexes after cellular detachment, whereas activa-
tion of PKA completely eliminated the co-immunopre-
cipitation of Abl activity with VASP. These data estab-
lish a new biochemical link between cell adhesion and
regulation of VASP proteins and provide the first dem-
onstration of a regulated interaction between VASP and
Abl in mammalian cells.
Integrin-mediated cell adhesion to the extracellular matrix
(ECM)1 provides positional and morphological information cru-
cial for temporal and spatial regulation of cellular events such
as proliferation, differentiation, cell movement, and cell death
(1). The influence of cell adhesion stems from both the physical
anchoring afforded by integrin-ECM interaction and genera-
tion of signals that communicate the state of adhesion to the
cell interior (1, 2). One of the most important responses to these
signals is the assembly and organization of the cytoskeleton,
particularly actin microfilaments. Integrity of the actin cy-
toskeleton establishes, maintains, and monitors cell shape and
is required for efficient transduction of signals initiated by
receptors at the cell surface, such as receptors for growth fac-
tors and G-protein agonists (1–3). Moreover, actin filament
polymerization and tension against filaments drives leading
edge protrusion and cell body translocation during cell move-
ment (4). Thus, identifying targets of adhesion-dependent sig-
naling that regulate the cytoskeleton is an important step
toward understanding how adhesion influences cell behavior.
The cAMP-dependent protein kinase (PKA) is activated upon
both cellular detachment (5) and, paradoxically, upon engage-
ment of integrins (6, 7). Indeed, some facets of cytoskeletal
assembly and integrity require PKA activity (e.g. activation of
Rac (6), Cdc42 (8), and F-actin synthesis (7)), whereas others
appear to be inhibited by it (e.g. activation of Rho (9) and
p21-activated kinase (5) and Tyr phosphorylation of focal ad-
hesion kinase and paxillin (10, 11)). Finally, both inhibition
and hyper-activation of PKA inhibit cell migration (6, 12).
These ostensibly disparate observations outline a complex role
for PKA in cytoskeletal regulation and suggest that factors that
regulate the actin cytoskeleton may be affected by anchorage-
dependent changes in PKA activity.
As a major substrate for PKA and a crucial regulator of actin
dynamics, the vasodilator-stimulated phosphoprotein (VASP)
is an excellent candidate target for anchorage-dependent reg-
ulation by PKA. The VASP family of actin regulatory proteins
(including the Drosophila-Enabled (Ena) protein, its mamma-
lian homolog (Mena), and the Ena/VASP-like protein (Evl))
share a common, three-domain structure comprising an N-
terminal Ena/VASP homology (EVH) type 1 domain, a central
Pro-rich region, and a C-terminal EVH2 domain (13, 14). VASP
family proteins localize to focal adhesions, largely through
EVH1-mediated interaction with vinculin, zyxin, and palladin
(14–16) and to filopodial tips and lamellipodial edges through
a less clear mechanism that may involve the EVH2 domain (17,
18). The EVH2 domain mediates homo- and heterotypic oli-
gomerization among VASP proteins (19), as well as the ability
of the protein to bind, bundle, and nucleate actin filaments (19,
20). The Pro-rich region mediates interaction with the profilin
family of monomeric actin-binding proteins (13, 14, 21), as well
as with the SH3 domains of the Abl and Src-family tyrosine
kinases (13, 21, 22).
The functions of VASP/Ena proteins are regulated by phos-
phorylation and all mammalian VASP family members (VASP,
Mena, and Evl) are substrates for PKA (14). For murine VASP,
phosphorylation occurs at three residues: Ser-153 near the
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Pro-rich region and Ser-235 and Thr-274 in EVH2 (positions
157, 239, and 278 in human VASP) (14, 23). Although each site
can be modified by both PKA and the cGMP-dependent protein
kinase, Ser-153 is the preferred target for PKA (23, 24). Only
two of these sites, corresponding to Ser-153 and Ser-235, are
present in Mena (13), whereas Evl contains only a single,
Ser-153-like site (22). PKA-mediated phosphorylation of VASP
and Evl decreases but does not completely eliminate their
ability to nucleate, bind, and bundle actin filaments (22, 25).
Phosphorylation near the Pro-rich regions of VASP proteins
also regulates interactions with SH3 domains (13, 21, 22, 25).
For example, phosphorylation of Evl by PKA has been shown to
abolish its interaction with Abl and neuronal Src SH3 domains
(22). And although Drosophila Ena is not phosphorylated by
PKA, it is Tyr-phosphorylated by Abl near the Pro-rich region
(26, 27), which inhibits its interaction with Abl and Src (27).
Interestingly, phosphorylation near the Pro-rich region of
VASP proteins does not disrupt profilin binding and has no
effect on EVH1-mediated interactions or EVH2-mediated oli-
gomerization (13, 14, 22, 25). Thus, the interaction of VASP
proteins with SH3 domains may represent a specific target for
regulation by PKA. This report unites the concepts discussed
above by demonstrating that cell adhesion dynamically regu-
lates PKA activity, which in turn regulates VASP phosphoryl-
ation and interaction with Abl in vivo.
EXPERIMENTAL PROCEDURES
Antibodies—Antibodies against VASP include: a mouse monoclonal
(Transduction Laboratories), diluted 1:1000 for immunoblotting REF52
and MDCK lysates; a rabbit polyclonal (Alexis Biochemicals), used for
immunoblotting (at 1:2000) and immunoprecipitation (at 1 l of anti-
body per 200 g of cell lysate) from NIH3T3 cells; a phospho-specific
rabbit polyclonal antibody, used at 1:1000 to visualize phosphorylation
at Ser-153 (a generous gift of Dr. Qingyuan Ye (Cell Signaling)); and a
phospho-specific polyclonal, used at 1:500 to visualize phosphorylation
at Ser-235 (Upstate Biotechnology). A mouse monoclonal IgA antibody
(Transduction Laboratories) was used at 1:500 to visualize Mena.
Antibodies to Abl include a monoclonal (8E9; Transduction Laborato-
ries), used at 1:250 for immunoblotting, and a rabbit polyclonal (K12;
Santa Cruz Biotechnology), used for immunoprecipitation and kinase
assays as described below and elsewhere (28). Epitope-tagged VASP
was immunoprecipitated with a monoclonal antibody against a vesicu-
lar stomatitis virus (VSV) glycoprotein antigen (BD Biosciences).
Horseradish peroxidase-conjugated secondary antibodies were from
Santa Cruz Biotechnology or Calbiochem and routinely used at 1:5000.
Cell Culture—NIH3T3 fibroblasts were maintained in DMEM with
10% bovine calf serum. REF52 and WI38 fibroblasts and MDCK epi-
thelial cells were maintained in DMEM with 10% fetal bovine serum.
Neo and dnPKA cells were maintained in NIH3T3 medium supple-
mented with 1 mg/ml active G418. ECV304 endothelial cells were
maintained in Medium 199 with 10% fetal bovine serum. For all cell
lines and experiments, cells were grown to near-confluence, then
serum-starved overnight (12–16 h) in media containing 0.1% serum.
Forskolin (Fsk) and isobutyl methylxanthine (IBMX) (Sigma) were
dissolved in Me2SO and added to cells (at 25 and 50 M, respectively) for
20 min. PDGF-BB (Upstate Biotechnology) was used at a final concen-
tration of 20 ng/ml. Detachment and replating on fibronectin (FN)- or
collagen-coated plates was performed as described (5). Briefly, cells
were detached with trypsin-EDTA and collected into DMEM containing
1% bovine serum albumin (BSA) and 1 mg/ml soybean trypsin inhibitor.
After centrifugation for 5 min at 500  g, cells were washed once and
resuspended in DMEM-BSA, then incubated in suspension with gentle
rotation for the indicated period of time. For replating, 10-cm Petri
dishes were coated with PBS containing 10 g/ml FN (BD Life Sciences)
or 20 g/ml type-I collagen from rat tail (Biomedical Technologies Inc.)
for 2 h at room temperature, then washed with PBS, and blocked for 30
min with DMEM  2% BSA.
Plasmids and Transfections—A pcDNA3-based plasmid encoding
VSV-tagged human VASP (24) and empty pCMV5 or pCMV5 encoding
the Myc-tagged form of the PKA inhibitor, PKI, (5), were transfected
into NIH3T3 cells using SuperFect (Qiagen) according to the manufac-
turer’s protocol. Twenty-four h later, cells were serum-starved and
cultured as described above.
Cell Lysis, Immunoblotting, Immunoprecipitation, and Abl Kinase
Assays—Cells were washed twice with ice-cold phosphate buffered sa-
line, then lysed in Triton lysis buffer (1% Triton X-100, 50 mM Tris, pH
7.4, 25 mM -glycerophosphate, 150 mM NaCl, 2 mM EDTA, 2 mM
EGTA, 10% glycerol) containing protease and phosphatase inhibitors,
using 750 l per 10-cm dish. After 10 min on ice, lysates were scraped
into microcentrifuge tubes and centrifuged at 14,000 rpm (in an Eppen-
dorf microcentrifuge) for 15 min at 4 °C. Protein concentration of the
supernatant lysate was determined by bicinchoninic acid assay (Pierce).
For direct immunoblotting, aliquots of lysate were mixed with an equal
volume of 2 Laemmli sample buffer and boiled for 5 min before loading
on 10% (for VASP) or 7.5% (for Mena and Abl) SDS-PAGE gels. For
VASP immunoprecipitation, 0.8–1.0 mg of protein was incubated with
anti-VASP or anti-VSV antibody for 1.5 h at 4 °C. Immunocomplexes
were collected by incubation with protein A/G-agarose beads (Santa
Cruz Biotechnology) for 30 min at 4 °C, washed four times with lysis
buffer, then resuspended, and boiled in 1 Laemmli sample buffer. For
some experiments, polyclonal VASP antibody was chemically cross-
linked to beads using dimethyl pimelimidate (Pierce) according to the
supplier’s protocol. Abl immunoprecipitation kinase assays were per-
formed essentially as described elsewhere (28). Briefly, c-Abl was im-
munoprecipitated from 200 g of protein using 2 g of K12 anti-Abl
antibody. Immunocomplexes were washed twice with lysis buffer sup-
plemented with 0.1% SDS and 1% sodium deoxycholate, twice with lysis
buffer, twice with lysis buffer without NaCl, and twice with kinase
buffer (20 mM Tris, pH 7.4, 10 mM MgCl2, 1 mM dithiothreitol). VASP
immunoprecipitates were prepared and processed for Abl kinase activ-
ity by immunoprecipitating VASP from 1 mg of protein and washing
immunocomplexes six times with lysis buffer then twice with kinase
buffer. Kinase reactions were carried out in 20 l of kinase buffer
containing 1 M ATP, 5Ci [-32P]ATP, and 0.5 g of GST-Crk and were
incubated for 40 min at 27 °C. Reactions were stopped by the addition
of an equal volume of 2 Laemmli sample buffer and boiled for 5 min.
Reaction products were separated on 10% SDS-PAGE gels, which were
Coomassie-stained, dried, and exposed to a PhosphorImager plate (Mo-
lecular Dynamics). For kinase assays using a peptide substrate instead
of GST-Crk, reactions were stopped by the addition of 5 l of 100 mM
EDTA and 20 l of the stopped reaction was spotted onto phosphocel-
lulose columns (Pierce), which were subsequently washed twice with
150 mM phosphoric acid and analyzed by liquid scintillation counting.
PKA Activity Assay—PKA activity was measured exactly as de-
scribed previously (5). Briefly, cells in suspension or on FN-coated
plates were rapidly washed twice with ice-cold PBS, then resuspended
or covered in PKA assay buffer and snap frozen in liquid nitrogen.
Lysates were thawed on ice, scraped into tubes (for adherent cells), then
sonicated and clarified by centrifugation at 10,000  g for 10 min at
4 °C. Supernatants were assayed for PKA activity by measuring trans-
fer of radioactive phosphate from ATP into Kemptide (Sigma) in the
presence or absence of purified PKI (Cell Signaling).
RESULTS
Cellular Detachment Promotes Phosphorylation of VASP and
Mena—To investigate whether VASP phosphorylation is af-
fected by changes in cell adhesion, NIH3T3 cells were serum-
starved overnight, then left untreated, stimulated with Fsk 
IBMX for 20 min or detached and incubated in suspension for
1 h. Extracts were then analyzed by immunoblotting with
anti-VASP antibodies. Phosphorylation of VASP at Ser-153,
the preferred PKA site, but not at Ser-235 or Thr-274, causes a
significant electrophoretic mobility shift of VASP on SDS-
PAGE gels (23, 24), and this shift is routinely used as a faithful
indicator of Ser-153 phosphorylation (24, 25). In untreated,
stably adherent cells, VASP was predominantly in the faster
migrating, unphosphorylated form (Fig. 1A). Detachment of
cells induced phosphorylation of VASP at Ser-153 almost as
efficiently as treatment with Fsk  IBMX. (Fig. 1A). This effect
was confirmed by immunoblotting with a phospho-specific an-
tibody that recognizes VASP only when phosphorylated near
the Pro-rich region (pSer-153 in murine and pSer-157 in hu-
man VASP; Fig. 1B). Detachment-induced phosphorylation of
VASP at Ser-153 (or the analogous position) was observed in
several cell lines, including rat embryo fibroblasts (Fig. 1A,
REF52), MDCK epithelial cells (Fig. 1C), and in human fibro-
blast (WI38) and endothelial (ECV304) cell lines (data not
shown).
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As apparent in Fig. 1B, a higher molecular weight band was
routinely detected in immunoblots using the phospho-Ser 153
antibody and behaved similarly to VASP in response to various
experimental treatments, suggesting that it may be a VASP
family member. Mena has at least three splice variants, gen-
erating proteins of 80, 88, and 140 kDa (13), and thus repre-
sented a likely candidate for this protein. Moreover, because
Mena, like VASP, is expressed in fibroblasts and epithelial
cells, is phosphorylated by PKA, and exhibits altered mobility
when phosphorylated (13), the effect of detachment on Mena
phosphorylation was directly investigated. Like VASP, Mena
was phosphorylated both in cells treated with Fsk  IBMX
and, significantly, in cells placed in suspension (Fig. 1D). The
mobility shift of VASP proteins is due to phosphorylation near
the Pro-rich region. To determine whether detachment also
affected phosphorylation near the EVH2 domain, immunoblots
were probed with a phospho-Ser-239 specific antibody. The
basal level of Ser-239 phosphorylation in quiescent, adherent
cells did not increase following detachment (Fig. 1E). In total,
these data demonstrate that cellular detachment induces phos-
phorylation of VASP family proteins specifically near the Pro-
rich region at sites preferred by PKA.
Dynamic Regulation of VASP Phosphorylation by Cell Adhe-
sion and during Cell Spreading—To determine if the detach-
ment-induced phosphorylation of VASP and Mena was revers-
ible, detached cells were replated onto dishes coated with FN
(for fibroblasts) or type-I collagen (for epithelial cells) and har-
vested for immunoblot analysis. Both Ser-153 of VASP and the
equivalent residue near the Pro-rich region of Mena were rap-
idly dephosphorylated following adhesion to ECM as judged by
the increased electrophoretic mobility of the proteins (Fig. 1,
C–E). Interestingly, although detachment did not promote sig-
nificant phosphorylation of VASP at Ser-235, this site, like
Ser-153, was rapidly dephosphorylated upon adhesion to ECM
(Fig. 1E).
To further investigate the dynamics of regulation of VASP
phosphorylation by adhesion, a detailed time course was per-
formed (Fig. 2A). Conversion of VASP to its phospho-Ser 153
form was more than 60% complete within 10 min after NIH3T3
cell detachment and more than 95% complete after 1 h (Fig. 2A,
left panel). Interestingly, the rapid and complete dephosphoryl-
ation of Ser-153 seen early after adhesion to FN was followed
by a period of intermediate phosphorylation as cells continued
to spread (Fig. 2A, right panel and B). By 1 h after plating,
VASP phosphorylation returned to a low baseline level equiv-
alent to that seen in stably adherent cells (Fig. 2A, right panel
and B). A similar bi-phasic course of phosphorylation, with
slightly different kinetics, was observed in epithelial cells that
had been detached and replated onto collagen (Fig. 2C). Light
microscopy showed both cell types to be firmly attached but
rounded at the early time points during which Ser-153 was
dephosphorylated (data not shown). During the later time
points at which VASP phosphorylation was intermediate, cells
were actively spreading and exhibited multiple lamellipodia
and extensive membrane ruffling, while the later decrease in
phosphorylation corresponded with a contractile, polygonal
morphology. These data suggest that phosphorylation of VASP
at Ser-153 changes dynamically in response to changes in cell
adhesion and also during cell spreading.
Activation of Protein Kinase A during Cell Spreading—The
increase in Ser-153 phosphorylation of VASP during cell
spreading suggested that PKA might become activated over the
same time course. To address this, PKA activity was measured
in NIH3T3 cells at various times after detachment and replat-
ing onto FN (Fig. 2D). As reported previously (5), PKA activity
was high in cells soon after detachment but decreased as cells
remained in suspension. The observed decrease in PKA activity
with prolonged incubation in suspension is in contrast to the
sustained phosphorylation of VASP at Ser-153 (compare Fig.
2A, left panel with D). The reasons for this disparity are cur-
rently unknown. However, following adhesion to FN, PKA ac-
tivity decreased initially but increased during cell spreading
and returned to baseline at later time points, a time course that
closely paralleled Ser-153 phosphorylation. These data corre-
late changes in PKA activity with changes in VASP phospho-
rylation at Ser-153 during cell adhesion and cell spreading.
Regulation of VASP-Abl Interaction by Cell Adhesion and
Cell Spreading—Adhesion-dependent changes in VASP phos-
phorylation near the Pro-rich region at Ser-153 may affect
VASP interaction with SH3 domains in vivo. To investigate
this, VASP immunoprecipitates from stably adherent and de-
tached cells were analyzed for the presence of Abl and Src. For
unknown reasons, attempts to co-immunoprecipitate Src with
VASP under a variety of conditions proved unsuccessful (data
not shown). However, Abl was routinely detected in VASP
immunoprecipitates from stably adherent cells (Fig. 3) and was
therefore chosen for further investigation. The readily detect-
able interaction between VASP and Abl observed in stably
adherent cells was ablated by treatment with Fsk  IBMX and,
importantly, by cellular detachment (Fig. 3, A–C), in a manner
paralleling VASP phosphorylation (Fig. 3, A–C). A time course
showed that the level of Abl that co-precipitated with VASP
increased significantly upon initial cellular adhesion to FN, fell
slightly as VASP phosphorylation increased during cell spread-
ing, and settled over time to levels comparable to those seen in
stably adherent cells (Fig. 3C). These data represent the first
demonstration of interaction between VASP and full-length
Abl in vivo and demonstrate dynamic regulation of this inter-
action by cell adhesion and spreading.
PKA Regulates Anchorage-dependent VASP-Abl Interac-
tion—Data thus far suggest that adhesion-dependent changes
in PKA activity regulate VASP phosphorylation, which in turn
FIG. 1. Cell adhesion controls phosphorylation of VASP and
Mena. Serum-starved cells (NIH3T3 (A, B, D, E), REF52 (A), or MDCK
(C)) were left adherent to tissue culture plates (TC), treated for 20 min
with 25 M Fsk and 50 M IBMX (F/I), detached, and cultured in
suspension for 1 h (Sp) or replated for 15 or 20 min onto dishes coated
with fibronectin (FN 15) or collagen (Coll 20) as indicated. Lysates were
analyzed with antibodies against total VASP, the phosphorylated form
of Ser-153 (Ser-157 in human VASP; pSer157-VASP) or Ser-235
(pSer239), or Mena, as indicated. Lines and numbers beside the panels
indicate the position of molecular mass markers (50 kDa for C and E).
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regulates VASP-Abl interaction. To reinforce these observa-
tions, the effect of cell adhesion on VASP phosphorylation and
VASP-Abl interaction was examined in cells in which PKA was
inhibited. dnPKA cells are a stable NIH3T3 cell line in which
activation of PKA, including that elicited by cellular detach-
ment (5) and cell spreading,2 is blocked by expression of a
dominant negative regulatory subunit of PKA (5). The basal
level of VASP phosphorylation in stably adherent cells and the
increased phosphorylation induced by Fsk  IBMX were sig-
nificantly inhibited in dnPKA cells (Fig. 3D). More importantly,
the detachment-induced phosphorylation of VASP, readily de-
tected in NIH3T3 cells and a control stable cell line (Neo), was
completely absent in dnPKA cells (Fig. 3D). A similar effect was
seen when PKA was inhibited by the PKA inhibitor protein,
PKI; transient expression of PKI inhibited phosphorylation of
epitope-tagged VASP in non-adherent cells (Fig 3E, lower pan-
el). Significantly, inhibition of VASP phosphorylation in non-
adherent cells promoted anchorage-independent interaction of
VASP with Abl (Fig. 3E, upper panel). These data demonstrate
that adhesion-dependent changes in PKA activity regulate
VASP phosphorylation and the adhesion-dependent interac-
tion between VASP and Abl.2 A. Howe, unpublished observations.
FIG. 2. VASP phosphorylation is dynamically regulated by cell adhesion and during cell spreading and correlates with PKA
activity. A and B, NIH3T3 cells were detached from tissue culture plates and incubated in suspension or held in suspension for 1 h and replated
on FN for the indicated times before harvesting and analysis by immunoblotting with antibodies against total VASP (A) or against pSer157-VASP
(B). Lysates from stably adherent (Adh) cells and cells treated with Fsk  IBMX (FI) were included as references for unphosphorylated and fully
phosphorylated VASP, respectively. 0 min after detachment indicates stably adherent cells, whereas 0 min after replating indicates cells held in
suspension for 1 h. C, MDCK cells were detached and held in suspension (Susp) or replated on collagen for the indicated number of minutes, then
harvested, and analyzed by VASP immunoblotting. D, NIH3T3 cells were detached and held in suspension (Susp) or replated on FN for the
indicated number of minutes and then harvested for PKA activity assay. The average and standard error from three separate experiments are
shown.
FIG. 3. The interaction of VASP with Abl is anchorage-dependent and controlled by PKA. A, VASP immunoprecipitates (IP) from
NIH3T3 cells stably adherent to tissue culture plates (TC) or cultured in suspension for 1 h (Sp) were analyzed by immunoblotting with c-Abl
antibody. B, an experiment similar to A with the inclusion of an IP from Fsk-treated cells and 40 g of whole cell extract (WCE) for control and
reference. For both A and B, a portion of each extract was reserved prior to immunoprecipitation and analyzed by VASP immunoblot as indicated.
C, chemically cross-linked anti-VASP beads were used to immunoprecipitate VASP from lysates from stably adherent cells (TC), Fsk  IBMX
(F/I)-treated cells, and cells incubated in suspension for 1 h (Sp) or re-plated on FN for the indicated number of minutes. Eighty and 20% of the
immunoprecipitates were analyzed by anti-Abl and anti-VASP immunoblotting, respectively. Ten g of whole cell extract (WCE) were run for
reference. D, adherent NIH3T3, Neo, or dnPKA cells were left untreated (), treated with Fsk  IBMX (F/I), or detached and cultured in
suspension for 1 h (Sp). Lysates were analyzed by VASP immunoblotting. The arrowhead indicates the position of a 50-kDa marker. E, NIH3T3
cells were transiently transfected with a plasmid encoding VSV-tagged VASP and either an empty control vector (Vec) or one encoding the PKA
inhibitor protein (PKI). After recovery, cells were serum-starved and left attached to tissue culture plates (TC) or detached and cultured in
suspension for 1 h (Sp) and then harvested for immunoprecipitation with anti-VSV antibody and analysis by VASP and Abl immunoblotting.
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Association of Abl Kinase Activity with VASP—The associa-
tion of Abl with VASP prompted investigation of whether Abl
kinase activity was also associated with VASP. To address this,
Abl and VASP immunoprecipitates were isolated from quies-
cent, stably adherent NIH3T3 cells and processed for Abl tyro-
sine kinase assay using GST-Crk as a substrate. Phosphoryla-
tion was assessed by SDS-PAGE separation of reaction
products and PhosphorImager analysis. Specific modification
of tyrosine residues in GST-Crk was confirmed by immunoblot-
ting with anti-phosphotyrosine antibodies (data not shown).
Only basal levels of kinase activity were present in Abl immu-
noprecipitates (Fig. 4A, upper panel), and little significant ac-
tivity was detected in VASP immunoprecipitates (Fig. 4A,
lower panel). Stimulation of cells with PDGF (28) stimulated
Abl activity nearly 4-fold in Abl immunoprecipitates (Fig. 4, A
and B) and, importantly, nearly 6-fold in VASP immunopre-
cipitates (Fig. 4, A and B). Pretreatment of cells with Fsk 
IBMX had no effect on the ability of PDGF to stimulate Abl
activity or to activate Abl but completely eliminated the co-
precipitation of PDGF-stimulated Abl activity with VASP (Fig.
4, A and B). Similar results were also seen using a commer-
cially available, optimized peptide as the substrate for Abl
(data not shown). These data demonstrate that PKA can reg-
ulate the association of Abl activity with VASP in vivo.
DISCUSSION
This work describes the dynamic, multiphasic activation of
PKA by cellular detachment, adhesion, and spreading and
links this activity to regulation of VASP phosphorylation and
interaction with the Abl proto-oncogene product. This is the
first demonstration of a biochemical link between cell-matrix
adhesion and regulation of the VASP family of cytoskeletal
regulatory proteins, as well as the first demonstration of the
interaction of VASP with full-length Abl protein in vivo.
Like VASP/Ena proteins, Abl is an important regulator of
cytoskeletal dynamics. Abl is activated and transiently local-
ized to focal adhesions upon adhesion to ECM (29), which may
be mediated by several proteins known to bind Abl (e.g. paxillin
(30), Abl-interacting (Abi) proteins (31), Crk (32), VASP (Ref.
14 and this study). Furthermore, domains in the C terminus of
Abl direct binding to both monomeric actin and actin filaments
(33); binding to F-actin inhibits Abl and appears to mediate the
anchorage dependence of Abl activity (34). Physiological acti-
vation of Abl is required for actin cytoskeletal remodeling in
response to growth factors (28), whereas oncogenic activation of
Abl induces transformation characterized by anchorage-inde-
pendent cell division and dramatic changes in cell morphology
(35). A recent report has shown that Abl drives the formation of
filopodia-like microspikes (34). Importantly, VASP proteins are
also known to localize to and promote the formation of these
structures (17, 18, 36). These observations, plus genetic and
biochemical evidence from Drosophila (37), emphasize the po-
tential importance of VASP-Abl interaction and its regulation
by PKA.
The direct effect of VASP-Abl interaction on the activity of
either protein is unknown. Except for a neural-specific variant
of Mena, mammalian VASP proteins do not appear to be Tyr-
phosphorylated (13), so their regulation by Abl must occur
through a mechanism other than direct phosphorylation. One
possibility is given by the fact that Abl can compete with
profilin for binding to Mena and Evl (13, 22) and, therefore,
perhaps also to VASP. As profilin binding is not inhibited by
phosphorylation, PKA-mediated phosphorylation of VASP pro-
teins would promote dissociation of Abl, which may facilitate
formation of profilin-containing complexes. Finally, Abl may
also modulate VASP function by phosphorylating VASP effec-
tors or binding partners; of note, both vinculin and zyxin are
phosphoproteins and contain sequences that resemble known
consensus sites for Abl phosphorylation (38).
VASP may also directly alter Abl activity. The Abl SH3
domain is crucial for the intramolecular folding that holds Abl
in a catalytically inactive conformation (39). Moreover, the
kinase activity of Abl is increased by the interaction of its SH3
domain with many, but not all, Abl-interacting proteins (40).
Thus, VASP may either directly activate Abl or may preferen-
tially interact with unfolded, activated Abl. Of course, interac-
tion with VASP would also presumably bring Abl into close
proximity to actin filaments, which may inhibit Abl activity by
engaging its F-actin binding domain (34). The balance of these
effects in vivo is currently unknown.
VASP-Abl interaction may help localize Abl activity to adhe-
sive or cytoskeletal structures (e.g. focal adhesions, filopodia)
and thereby facilitate modification of Abl targets within those
structures. Regulating this localization via phosphorylation of
VASP is an attractive function for adhesion-dependent changes
in PKA activity. Indeed, altered regulation of VASP-Abl inter-
action may contribute to the anchorage-independent growth
factor signaling and blunted cell migration observed in dnPKA-
expressing cells (5, 12). Phosphorylation of VASP proteins does
not affect EVH1-mediated interactions (15, 25). Consistent
with this, VASP-vinculin complexes are not disrupted in de-
tached cells.3 Thus, activation of PKA may selectively displace
Abl without affecting EVH1-mediated VASP localization.
While global changes in cell adhesion (e.g. detachment and
reattachment) and PKA activity have sweeping effects on
VASP-Abl interaction, localized changes in adhesion and PKA
activity may affect distinct, localized VASP-Abl complexes. The
intricate anchoring of PKA to various subcellular locales via
protein kinase A anchoring proteins provides a conduit for this
type of spatial control (41). Of particular interest in this regard
3 K. DeMali and K. Burridge, manuscript in preparation.
FIG. 4. PKA regulates the association of Abl tyrosine kinase
activity with VASP. A, NIH3T3 cells were treated for 20 min with
Me2SO (0.2% v/v) or Fsk  IBMX and then left untreated or stimulated
for 5 min with PDGF as indicated. Cells were lysed, and immunopre-
cipitations using antibodies against Abl or VASP were processed for Abl
kinase assay using [32P]ATP and GST-Crk as substrates. Reaction
products were either separated by SDS-PAGE and visualized (A) or
quantitated (B) by PhosphorImager analysis.
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is the interaction of PKA with WAVE, a member of the Wiskott-
Aldrich Syndrome protein family, that localizes to lamellipodia
and other actin-rich structures and also interacts with Abl in
vivo (18, 42). As both WAVE and VASP bind to the Abl SH3
domain, their binding would be mutually exclusive. It is
therefore tempting to posit that WAVE-mediated recruit-
ment of PKA may serve to regulate the balance of Abl-WAVE
and Abl-VASP complexes (and perhaps VASP-profilin, as
mentioned above). This putative equilibrium and its func-
tional consequences have yet to be identified, but efforts are
underway.
Cell adhesion may affect other aspects of VASP function in
addition to VASP-Abl interaction. As phosphorylation has been
shown to inhibit the ability of VASP proteins to nucleate, bind,
and bundle F-actin, dephosphorylation of VASP upon adhesion
may promote microfilament nucleation and bundling, which
may facilitate initial cell spreading. Interestingly, dephospho-
rylation of VASP is mediated in part by protein phosphatase 2A
(14, 43), which has recently been shown to be activated by
integrin engagement (44). Equilibrium between phosphoryl-
ated and non-phosphorylated forms later during cell spreading
may be required for dynamic association of VASP with remod-
eling microfilaments. The return to a predominantly dephos-
phorylated form of VASP as cells become polygonal may reflect
an increase in VASP F-actin bundling, which may enhance
stress fiber formation.
The present work places phosphorylation of VASP proteins
by PKA and the subsequent regulation of VASP-Abl interaction
at the nexus of cell adhesion and cytoskeletal dynamics and
may have broad implications for regulation of cell motility and
anchorage-dependent cell growth.
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